Martijn J. Wilmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martijn J. Wilmer has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Rosalinde Masereeuw
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University. Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
4 shared publications Tom T. G. Nieskens
Department of Pharmacology and Toxicology (149), Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands
3 shared publications- Frans G. M. Russel
Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, Netherlands, The Netherlands
2 shared publications Henriëtte L. Lanz
Mimetas BV, Leiden, The Netherlands
2 shared publicationsJanny G. P. Peters
Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands (T.T.G.N., J.G.P.P., D.D., D.K., K.J., A.H.V.A., F.G.M.R., M.J.W.); Department of Physical Chemistry/Bioenergetics, Institute of Chemistry PC14, Technical University of Berlin, Berlin, Germany (N.N.T., T.F.); and Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands (K.J., R.M.).
2 shared publicationsKatja Jansen
Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands (T.T.G.N., J.G.P.P., D.D., D.K., K.J., A.H.V.A., F.G.M.R., M.J.W.); Department of Physical Chemistry/Bioenergetics, Institute of Chemistry PC14, Technical University of Berlin, Berlin, Germany (N.N.T., T.F.); and Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands (K.J., R.M.).
2 shared publications
Latest Publications
- Open Access
- 26 July 2018
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (5) , 87
Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip
Drug-transporter interactions could impact renal drug clearance and should ideally be detected in early stages of drug development to avoid toxicity-related withdrawals in later stages. This requires...
- 26 July 2018
- Published by Springer Nature in The AAPS Journal
- Vol. 20 (5) , 87
Open AccessScreening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip
Drug-transporter interactions could impact renal drug clearance and should ideally be detected in early stages of drug development to avoid toxicity-related withdrawals in later stages. This requires...
- Open Access
- 1 May 2018
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (5) , 592-599
Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity
Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main adverse effect is organic cation transporter 2 (OCT2)–mediated nephrotoxicity, observed in 30% of patients. The contribution of other renal drug transporters is elusive. Here, cisplatin-induced toxicity was evaluated in human-derived conditionally immortalized proximal tubule epithelial cells (ciPTEC) expressing renal drug transporters, including OCT2 and organic anion transporters 1 (OAT1) or 3 (OAT3). Parent ciPTEC demonstrated OCT2-dependent cisplatin toxicity (TC50 34 ± 1 μM after 24-hour exposure), as determined by cell viability. Overexpression of OAT1 and OAT3 resulted in reduced sensitivity to cisplatin (TC50 45 ± 6 and 64 ± 11 μM after 24-hour exposure, respectively). This effect was independent of OAT-mediated transport, as the OAT substrates probenecid and diclofenac did not influence cytotoxicity. Decreased cisplatin sensitivity in OAT-expressing cells was associated directly with a trend toward reduced intracellular cisplatin accumulation, explained by reduced OCT2 gene expression and activity. This was evaluated by Vmax of the OCT2-model substrate ASP+ (23.5 ± 0.1, 13.1 ± 0.3, and 21.6 ± 0.6 minutes−1 in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3, respectively). Although gene expression of cisplatin efflux transporter multidrug and toxin extrusion 1 (MATE1) was 16.2 ± 0.3-fold upregulated in ciPTEC-OAT1 and 6.1 ± 0.7-fold in ciPTEC-OAT3, toxicity was unaffected by the MATE substrate pyrimethamine, suggesting that MATE1 does not play a role in the current experimental set-up. In conclusion, OAT expression results in reduced cisplatin sensitivity in renal proximal tubule cells, explained by reduced OCT2-mediated uptake capacity. In vitro drug-induced toxicity studies should consider models that express both OCT and OAT drug transporters.
- 1 May 2018
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (5) , 592-599
Open AccessExpression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity
Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main adverse effect is organic cation transporter 2 (OCT2)–mediated nephrotoxicity, observed in 30% of patients. The contribution of other renal drug transporters is elusive. Here, cisplatin-induced toxicity was evaluated in human-derived conditionally immortalized proximal tubule epithelial cells (ciPTEC) expressing renal drug transporters, including OCT2 and organic anion transporters 1 (OAT1) or 3 (OAT3). Parent ciPTEC demonstrated OCT2-dependent cisplatin toxicity (TC50 34 ± 1 μM after 24-hour exposure), as determined by cell viability. Overexpression of OAT1 and OAT3 resulted in reduced sensitivity to cisplatin (TC50 45 ± 6 and 64 ± 11 μM after 24-hour exposure, respectively). This effect was independent of OAT-mediated transport, as the OAT substrates probenecid and diclofenac did not influence cytotoxicity. Decreased cisplatin sensitivity in OAT-expressing cells was associated directly with a trend toward reduced intracellular cisplatin accumulation, explained by reduced OCT2 gene expression and activity. This was evaluated by Vmax of the OCT2-model substrate ASP+ (23.5 ± 0.1, 13.1 ± 0.3, and 21.6 ± 0.6 minutes−1 in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3, respectively). Although gene expression of cisplatin efflux transporter multidrug and toxin extrusion 1 (MATE1) was 16.2 ± 0.3-fold upregulated in ciPTEC-OAT1 and 6.1 ± 0.7-fold in ciPTEC-OAT3, toxicity was unaffected by the MATE substrate pyrimethamine, suggesting that MATE1 does not play a role in the current experimental set-up. In conclusion, OAT expression results in reduced cisplatin sensitivity in renal proximal tubule cells, explained by reduced OCT2-mediated uptake capacity. In vitro drug-induced toxicity studies should consider models that express both OCT and OAT drug transporters.
- 1 November 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 790, 46-56
Kidney-on-a-chip technology for renal proximal tubule tissue reconstruction
- 1 November 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 790, 46-56
Kidney-on-a-chip technology for renal proximal tubule tissue reconstruction
- Top Cited Papers
- 1 February 2016
- Published by Elsevier in Trends in Biotechnology
- Vol. 34 (2) , 156-170
Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening
- 1 February 2016
- Published by Elsevier in Trends in Biotechnology
- Vol. 34 (2) , 156-170
Top Cited PapersKidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening
- Open Access
- 28 January 2016
- Published by Springer Nature in The AAPS Journal
- Vol. 18 (2) , 465-475
A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity
Drug-induced nephrotoxicity still hampers drug development, because current translation from in vitro or animal studies to human lacks high predictivity. O
- 28 January 2016
- Published by Springer Nature in The AAPS Journal
- Vol. 18 (2) , 465-475
Open AccessA Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity
Drug-induced nephrotoxicity still hampers drug development, because current translation from in vitro or animal studies to human lacks high predictivity. O